中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系

黄蓉 倪加加 高毅

引用本文:
Citation:

肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系

DOI: 10.3969/j.issn.1001-5256.2018.06.041
基金项目: 

国家自然科学基金(81470875); 

详细信息
  • 中图分类号: R735.7

The association between the intestinal microbiota-lipopolysaccharide-Toll-like receptor 4 axis and hepatocellular carcinoma

Research funding: 

 

  • 摘要: 肝细胞癌是各种慢性肝病终末期的主要并发症,研究表明肝病患者普遍存在肠道屏障破坏和肠道菌群紊乱,导致肠道细菌移位,发生内毒素血症。Toll样受体4是肝内一种模式识别受体,能够结合内毒素中的活性成分——脂多糖,通过胞内一系列信号转导途径导致免疫炎症反应,最终促进肝纤维化和肿瘤发生。综述了肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌发病机制相关研究进展。

     

  • [1]LUO J, JIN F.Recent advances in understanding the impact of intestinal microbiota on host behavior[J].Chin Sci Bull, 2014, 59 (22) :2169-2190. (in Chinese) 罗佳, 金锋.肠道菌群影响宿主行为的研究进展[J].科学通报, 2014, 59 (22) :2169-2190.
    [2]YU LX, SCHWABE RF.The gut microbiome and liver cancer:mechanisms and clinical translation[J].Nat Rev Gastroenterol Hepatol, 2017, 14 (9) :527-539.
    [3]KIZILTAS S.Toll-like receptors in pathophysiology of liver diseases[J].World J Hepatol, 2016, 8 (32) :1354-1369.
    [4]WEI XP, GAO X, MA YJ.Relationship between small intestinal bacterial overgrowth and severity of with hepatitis B cirrhosis[J].J Clin Hepatol, 2016, 32 (4) :716-719. (in Chinese) 魏新朋, 高晓, 马英杰.乙型肝炎肝硬化患者小肠细菌过度生长与疾病严重程度的相关性[J].临床肝胆病杂志, 2016, 32 (4) :716-719.
    [5]BENTEN D, WIEST R.Gut microbiome and intestinal barrier failure——the"Achilles heel"in hepatology?[J].J Hepatol, 2012, 56 (6) :1221-1223.
    [6]WU ZW, XU KJ, LI LJ, et al.Investigation of intestinal bacterial translocation in 78 patients with cirrhosis after liver transplantation[J].Chin J Surg, 2006, 44 (21) :1456-1459. (in Chinese) 吴仲文, 徐凯进, 李兰娟, 等.78例肝硬化患者肠道细菌易位及其相关性研究[J].中华外科杂志, 2006, 44 (21) :1456-1459.
    [7]RACANELLI V, REHERMANN B.The liver as an immunological organ[J].Hepatology, 2006, 43 (2 Suppl 1) :s54-s62.
    [8]TAKEDA K, KAISHO T, AKIRA S.Toll-like receptors[J].Annu Rev Immunol, 2003, 21 (1) :335-376.
    [9]DAPITO DH, MENCIN A, GWAK GY, et al.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J].Cancer Cell, 2012, 21 (4) :504-516.
    [10]YOON HY, YI HY.Liver cirrhosis mortality in the United States, 1970-2007 surveillance report#88:NIAAA homepage 2010[EB/OL].http://pubs.niaaa.nih.gov/publications/surveillance88/Cirr07.htm, 2017-12-7.
    [11]REHM J, MATHERS C, POPOVA S, et al.Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders[J].Lancet, 2009, 373 (9682) :2223-2233.
    [12]SANYAL AJ, YOON SK, LENCIONI R.The etiology of hepatocellular carcinoma and consequences for treatment[J].Oncologist, 2010, 15 (Suppl 4) :14-22.
    [13]LIPPAI D, BALA S, CATALANO D, et al.Micro-RNA-155deficiency prevents alcohol-induced serum endotoxin increase and small bowel inflammation in mice[J].Alcohol Clin Exp Res, 2014, 38 (8) :2217-2224.
    [14]PRADERE JP, TROEGER JS, DAPITO DH, et al.Toll-like receptor 4 and hepatic fibrogenesis[J].Semin Liver Dis, 2010, 30 (3) :232-244.
    [15]SZABO G.Gut-liver axis in alcoholic liver disease[J].Gastroenterology, 2015, 148 (1) :30-36.
    [16]UESUGI T, FROH M, ARTEEL GE, et al.Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice[J].Hepatology, 2001, 34 (1) :101-108.
    [17]ADACHI Y, MOORE LE, BRADFORD BU, et al.Antibiotics prevent liver injury in rats following long-term exposure to ethanol[J].Gastroenterology, 1995, 108 (1) :218-224.
    [18]FAN JG, FARRELL GC.Epidemiology of non-alcoholic fatty liver disease in China[J].J Hepatol, 2009, 50 (1) :204-210.
    [19]MICHELOTTI GA, MACHADO MV, DIEHL AM.NAFLD, NASH and liver cancer[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :656.
    [20]STREBA LA, VERE CC, ROGOVEANU I, et al.Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma:An open question[J].World J Gastroenterol, 2015, 21 (14) :4103-4110.
    [21]ZHOU D, PAN Q, SHEN F, et al.Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J].Sci Rep, 2017, 7 (1) :1529.
    [22]SPRUSS A, KANURI G, WAGNERBERGER S, et al.Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice[J].Hepatology, 2009, 50 (4) :1094-1104.
    [23]PAPPO I, BERCOVIER H, BERRY EM, et al.Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide[J].JPEN J Parenter Enteral Nutr, 1992, 16 (6) :529-532.
    [24]PAPPO I, BECOVIER H, BERRY EM, et al.Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat[J].J Surg Res, 1991, 51 (2) :106-112.
    [25]DRENICK EJ, FISLER J, JOHNSON D.Hepatic steatosis after intestinal bypass——prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition[J].Gastroenterology, 1982, 82 (3) :535-548.
    [26]MIELE L, VALENZA V, LA TORRE G, et al.Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease[J].Hepatology, 2009, 49 (6) :1877-1887.
    [27]BROERING R, LU M, SCHLAAK JF.Role of Toll-like receptors in liver health and disease[J].Clin Sci (Lond) , 2011, 121 (10) :415-426.
    [28]SOARES JB, PIMENTEL-NUNES P, RONCON-ALBUQUERQUE R, et al.The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases[J].Hepatol Int, 2010, 4 (4) :659-672.
    [29]KAO JH, CHEN DS.Global control of hepatitis B virus infection[J].Lancet Infect Dis, 2002, 2 (7) :395-403.
    [30]CHEN DS.Fighting against viral hepatitis:Lessons from Taiwan[J].Hepatology, 2011, 54 (2) :381-392.
    [31]CHEN MM, ZHENG JS, LIU YY, et al.Changes of intestinal microbiota in patients with chronic hepatitis B and liver cirrhosis[J].Acta Univ Med Anhui, 2015, 50 (5) :648-652. (in Chinese) 陈萌萌, 郑吉顺, 刘艳艳, 等.慢性乙型肝炎以及肝硬化患者肠道微生物研究[J].安徽医科大学学报, 2015, 50 (5) :648-652.
    [32]LI LJ, WU ZW, MA WH, et al.Changes in intestinal microflora in patients with chronic severe hepatitis[J].Chin Med J, 2001, 114 (8) :86-89. (in Chinese) 李兰娟, 吴仲文, 马伟杭, 等.慢性重型肝炎患者肠道菌群变化及其作用的研究 (英文) [J].中华医学杂志, 2001, 114 (8) :86-89.
    [33]DOLGANIUC A, NORKINA O, KODYS K, et al.Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection[J].Gastroenterology, 2007, 133 (5) :1627-1636.
    [34] JIANG FM, LI XF, CHENG SQ, et al.Clinical significance of expression of TLR3 and TLR4 in liver tissue of patients with chronic hepatitis B[J].Int J Virol, 2017, 24 (3) :209-212. (in Chinese) 蒋福明, 李秀芬, 程书权, 等.慢性乙型肝炎患者肝组织Toll样受体3、4表达及其临床意义[J].国际病毒学杂志, 2017, 24 (3) :209-212.
    [35]SOARES JB, PIMENTEL-NUNES P, AFONSO L, et al.Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence[J].Innate Immun, 2012, 18 (5) :700-708.
    [36]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.
    [37]YU LX, YAN HX, LIU Q, et al.Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents[J].Hepatology, 2010, 52 (4) :1322-1333.
    [38]JING YY, HAN ZP, SUN K, et al.Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide[J].BMC Med, 2012, 10:98.
    [39]MACHIDA K, TSUKAMOTO H, MKRTCHYAN H, et al.Tolllike receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog[J].Proc Natl Acad Sci U S A, 2009, 106 (5) :1548-1553.
    [40]ZHANG HL, YU LX, YANG W, et al.Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J].J Hepatol, 2012, 57 (4) :803-812.
    [41]LI J, SUNG CY, LEE N, et al.Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J].Proc Natl Acad Sci U S A, 2016, 113 (9) :e1306-e1315.
  • 加载中
计量
  • 文章访问数:  1407
  • HTML全文浏览量:  16
  • PDF下载量:  323
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-12-11
  • 出版日期:  2018-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回